Werewolf Therapeutics, Inc. (HOWL)
0.9844
0.00 (0.00%)
USD |
NASDAQ |
Sep 11, 10:49
Werewolf Therapeutics Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 3.086 |
| December 31, 2025 | 1.519 |
| September 30, 2025 | 1.260 |
| June 30, 2025 | 0.8959 |
| March 31, 2025 | 0.6459 |
| December 31, 2024 | 0.5053 |
| September 30, 2024 | 0.4115 |
| June 30, 2024 | 0.3526 |
| March 31, 2024 | 0.436 |
| December 31, 2023 | 0.4662 |
| September 30, 2023 | 0.4641 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.4453 |
| March 31, 2023 | 0.4398 |
| December 31, 2022 | 0.12 |
| September 30, 2022 | 0.1158 |
| June 30, 2022 | 0.1197 |
| March 31, 2022 | 0.113 |
| December 31, 2021 | 0.1025 |
| September 30, 2021 | 0.0121 |
| June 30, 2021 | 0.0122 |
| March 31, 2021 | 0.0289 |
| December 31, 2020 | 0.0285 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 24.16M |
| Total Liabilities (Quarterly) | 7.863M |
| Shareholders Equity (Quarterly) | 16.29M |
| Current Ratio | 2.911 |
| Net Debt Paydown Yield | 42.32% |